Background: A significant proportion of screen-detected men with prostate cancer may be overdiagnosed. Active Surveillance (AS) has emerged as a way to mitigate this problem, by delaying treatment of men, who are at low-risk until this becomes necessary. However, it is not known after how much time or biopsy rounds should patients stop AS and transition to conservative management (CM), if no progression is detected.
| INTRODUCTION
Active Surveillance (AS) has emerged as a way to minimize overtreatment due to frequent PSA-based prostate cancer screening. It consists on the monitoring of newly diagnosed and not yet treated men through PSA tests and/or repeat biopsies. The goal of AS is to delay or avoid radical treatment in patients who are unlikely to become symptomatic 1. In the conservative management (CM) regimen patients are also monitored, although not with invasive procedures like, prostate biopsies, and without curative intent, unless the patient becomes symptomatic. It is similar to watchful waiting, though this term often refers only to older men, or with major comorbidities. 1 The majority of clinical cohorts following men on AS have a limited follow-up, which is not long enough to establish the longterm effects, [2] [3] [4] [5] [6] [7] however, there is an emerging consensus regarding the safety of AS for low-risk men, [8] [9] [10] and the rate of low-risk men assigned to AS is increasing rapidly. 11 Still there is substantial uncertainty about what is the most optimal way of performing AS, namely about whom to include and the follow-up protocol. [8] [9] [10] Computer modeling has been used to make projections of the potential effects of AS on prostate cancer mortality (PCM) and overtreatment. Previous studies 12, 13 found that compared to immediate treatment, AS results in a modest increase in PCM (1.4% and 1.8%, respectively). Others [14] [15] [16] [17] have compared the costs or cost-effectiveness of AS and/or CM to immediate treatment and found that AS seems to be more advantageous. As far as we know, no simulation study has tried to optimize the age to stop AS and start CM.
There are virtually no clinical studies on when can a patient safely discontinue AS, if no progression is detected and stop being considered for radical treatment, which may potentially lead to treatment decisions to depend on personal or physician's preferences. In the PRIAS cohort, the compliance with PSA testing during AS was relatively high, however, the compliance with prostate biopsies is relatively low and decreases rapidly over time from 81% at 1 year to 33% after 10 years. 18 A recent study 19 using SEER data found that only 13% of men underwent prostate biopsy after 2 years, in a community setting. For older patients or men suffering from significant comorbidities, this is probably reasonable, however, for patients with a longer life expectancy there could be a danger of progression to advanced disease, due to non-adherence to the biopsy protocol.
The aim of this study is to determine at which age it is safe and more cost-effective to leave AS and transition to a CM depending on their remaining lead-time (ie, time to clinical diagnosis in absence of screening) and age group, based on ERSPC data. We also modeled PSA growth from onset until detection. The parameters of the natural history, which include onset of the disease, durations, transition probabilities between health states, and PSA growth were calibrated to observed ERSPC's PSA distribution data and SEER incidence data 21, 22 and Supplemental
Information Fig. S1 .
At clinical detection, a baseline survival is assigned, which depends on Gleason score (<8 or ≥8) and was estimated based on SEER data from the pre-PSA era (1983) (1984) (1985) (1986) ). This was adjusted, for improvements on survival not directly associated with screening or primary treatment, by adding a hazard ratio for prostate cancer survival of 0.82, which was calibrated to the observed PCM in the ERSPC control (no screening) group (Supplemental Information Table S1 ).
We add a benefit of treatment and a benefit of screening (in case the patient is screen-detected) to the baseline survival. The hazard ratio for the benefit of treatment equals 0.56 for radical prostatectomy. 23 For radiation therapy this equals 0.63 using the same rationale as in. 24 The effect of screening is modeled through a lead-time dependent cure rate for non-metastatic cases, Cure probability ¼ expðcure parameter * lead À timeÞ:
The cure parameter was calibrated based on the observed prostate cancer mortality reduction due to screening in the ERSPC trial 25 and Supplemental Information Table S1 .
When the patient is referred to AS, natural history progresses as if the patient was not screen-detected. Referral to radical treatment may occur due to detection of Gleason or volume progression (which is assumed to occur after an increase in stage)
at each biopsy round, due to personal preference (randomly selected from all men in AS) or due to clinical detection at the time.
The probabilities of referral to radical treatment for low-risk men are estimated based on JH-AS observed treatment-free survival data 4 ( 
| Active surveillance
We simulate a cohort of 10 million men, based on US life tables. In the basecase, men are screened between 55 and the upper bound of the age group selected for AS (with an attendance rate of 90%), with a PSA threshold for biopsy referral of four and biopsy compliance equal to 41%, based on the PLCO trial. 26 Biopsy Compliance during AS is based on the PRIAS study 17 and Supplemental Information Table S2 .
We only follow men who are selected for AS in a particular age Initially, the rate of clinical diagnosis in absence of screening was based on the control group and interval cancers in the screening group of the ERSPC trial. Since the model was adapted to US, an extra hazard of clinical diagnosis was added, reflecting an earlier probability of detection. This was calibrated to SEER incidence data from before the introduction of PSA-based screening.
We assume that the main difference between AS and CM surveillance regimens is that AS includes prostate biopsies, that is, we assume a similar rate of PSA tests or visits to the doctor between the two regimens. We also assume that the main driver of referral to treatment while in AS is the result of the prostate biopsy.
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| Quality of life and costs
QALYs were calculated by using utility estimates ranging between 0 (death or worst imaginable health) and 1 (pre-diagnosis health, which is assumed to be full health). Estimates for the utilities and its durations for all stages of AS, including, prostate biopsies, radical treatment, post-recovery, and palliative therapy are based on [27] [28] [29] (Table 2 ).
QALYs were calculated by multiplying the loss in utility with the duration of the phase and the number of men who experienced the event, as predicted by MISCAN.
Costs of AS compared to CM include the cost of prostate biopsies
and the extra cost of radical treatment, since in CM regimen only men who are clinically diagnosed are treated. The cost of immediate treatment is the average lifetime cost for men treated at age 65, including adverse events, indirect costs, and post-treatment surveillance. 30 Costs of palliative therapy are based on. 31 All costs were inflated to 2015 US Dollars.
We calculate the cost per QALY using a 3% discount rate for all costs and effects. The most efficient AS policies are determined based on their incremental cost-effectiveness ratio (ICER). An AS protocol is considered to be cost-effective if its ICER is below $100 000.
| Outcomes
We estimated the cost-effectiveness of each AS protocol compared to CM (no treatment) for men who are selected to AS. The main outcome is cost per QALY gained of the AS protocol compared to CM. Other important outcomes include overtreatment, prostate cancer mortality, life years gained (LYG), and costs.
| Sensitivity analyses
We analyzed the effects of some plausible alternative scenarios. For the age groups 55-59 and 60-64, we studied whether a lower biopsy frequency (triannual after the first year) or a higher biopsy compliance (81% for the whole follow-up) would have a large impact on QALYs gained. For the age group 65-69, we projected the effects of starting screening at age 65, and we split the age group in smaller intervals (65-66, 65-67, 65-68). In order to assess the effect of uncertainty around the parameter estimates on the outcomes, several multivariate sensitivity analyses were performed, including the utility and cost estimates for each event, the parameters of the model related to treatment benefit, the benefit due to early detection, and the rate of clinical diagnosis.
3 | RESULTS
| Effects
In to the European situation.
FIGURE 1
In this example, we show the life history of a man who would be clinically diagnosed in absence of screening, and die from prostate cancer, but that could be saved by treating early. This man also experiences progression during AS, after the time of the first biopsy. In "AS, One Biopsy" protocol, AS stops after one biopsy, in "AS, two biopsies" protocol, AS stops after two biopsies
In 
| Costs
In Table 3 , the total cost of AS is shown. Cost of AS increases with number of biopsy rounds and age group. Cost varied between $0.9 million, per 1000 men in AS, for one biopsy for 55-59 men, and $8.2 million for men aged 70-74 after 10 biopsy rounds.
| Cost-effectiveness
We show the cost-effectiveness of AS compared to CM in Table 3 
| Other scenarios
Under the assumption that biopsy compliance during AS remains 81%
for the whole follow-up (observed biopsy compliance in the first year of the PRIAS 14), we see that after four biopsy rounds QALYs gained increase from 264 to 300 for the 55-59 age group, and from 118 to 131 for the 60-64 age group ( 
| Sensitivity analyses
Our sensitivity analyses focus on the age group 60-65. At four biopsy rounds we find a range for the ICER between $15 842 (50% higher costs) and $78 709 (unfavorable utilities for prostate biopsies and treatment). At seven biopsy rounds the ICER ranges between $20 329 Tables S7 and S8 ). The only scenario where AS after seven biopsy rounds was not cost-effective was when we applied unfavorable utilities toward screening and treatment procedures. By contrast, if we would apply more favorable utilities, lower costs, lower treatment benefit, and a higher rate of clinical diagnosis then AS would become cost-effective after 10 biopsy rounds (Supplemental Information   Tables S7 and S8 ).
| DISCUSSION
In this study, we tried to determine for the first time, how much time should men stay on AS and be considered for treatment. Previous clinical studies have ascertained AS is relatively safe for low-risk men. [2] [3] [4] [5] [6] [7] 11, 12 Additionally, most studies [14] [15] [16] [17] found that AS is less expensive or cost-effective than immediate treatment. However, no clinical cohort or simulation study has examined how much time should men be on AS or how the age group or life expectancy could determine the intensity of the follow-up schedule.
In this study, we find that AS with 7 yearly biopsy rounds for low-risk men is cost-effective compared to CM, but only for age The inclusion of low-risk men younger than 60 in AS is not consensual. 10 These are the best candidates for immediate treatment and have a relatively low probability of being overtreated. 32, 33 We find that if these men are included on AS, they require an intensive yearly biopsy schedule, which should continue for at least 10 yearly biopsy rounds. A low biopsy compliance or biopsy frequency may result in QALYs lost and in a significant increase in PCM.
By contrast, for men older than 70, AS is not cost-effective, and does not result in QALY's gained, though some lives are saved. For men aged between 60 and 64, AS appears to be cost-effective up to seven biopsy rounds, and for men aged 65-69 AS results on QALYs lost. With a finer analysis, we find that for men aged 65-67, and for men who started screening after age 65 AS results in QALYs gained but it is still not cost-effective. Just like for men younger than 60, selecting intermediate-risk men for AS is still under debate. 34 We find that if these men are selected, an intensive AS regime with many follow-up biopsies is recommended (for men younger than 70, at least 10 yearly biopsy rounds).
Sensitivity analyses found that the results in this study are the most sensitive to the utilities. For instance, using more unfavorable utilities about biopsies and treatment made the ICER become higher than $100 000 at 7 years for the age group 60-65. However, there were more scenarios (higher cure rate, lower treatment effect, favorable utilities), where AS with 10 yearly biopsy rounds became cost-effective. This study is subject to some limitations. Our AS model uses a simplification of the criteria of selection for AS and to be referred to treatment compared to most clinical cohorts. For instance, we do not model the number of positive biopsy cores and we assume volume progression can only occur, if there is an increase in T-stage.
The probabilities of referral to treatment are based on the JH cohort, which has slightly different selection criteria to AS and referral to treatment criteria than other cohorts like PRIAS or the Toronto cohort. 7 The JH cohort does contain mostly very-low risk men and no intermediate-risk men. We assume that given progression which is not dependent on JH data, the probability of referral to treatment is the same as for intermediate-risk men, low-risk men, and very lowrisk men (Except for volume progression which has higher probability of detection for low and intermediate-risk men than for very low-risk men). We also assume that all men whose progression is detected are referred to radical treatment, which may not happen in clinical practice. While most clinical cohorts find that AS for low-risk men is safe, there is still some debate about the most optimal way to perform AS. 
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